1.Therapeutic effects of sodium nitroprusside combined verapamil for no-reflow during percutaneous coronary intervention
Yingwen CHEN ; Yunzhao HU ; Yanxian WU ; Wensheng LI ; You YANG ; Linlin MAI ; Jiankai ZHONG
Chinese Journal of cardiovascular Rehabilitation Medicine 2017;26(4):416-419
Objective:To explore therapeutic effects of sodium nitroprusside (SNP) combined verapamil on no-reflow during percutaneous coronary intervention (PCI).Methods: A total of 106 patients, who suffered from no-reflow during PCI in our department from Jan 2011 to Dec 2013, were selected.According to random number table method, patients were divided into SNP group (n=55, received SNP based on routine treatment) and combined treatment group (n=51, received verapamil based on SNP group).Cardiac troponin I (cTnI) level before and 16h~18h after PCI, cardiac function indexes after 12-month follow-up, incidence of major adverse cardiovascular events (MACE) were measured and compared between two groups.Results: Compared with before PCI, there were significant rise in cTnI level in both groups on 16~18h after PCI, P=0.001 both;compared with SNP group, there were significant reductions in cTnI level [(1.31±0.44)μg/L vs.(0.11±0.02)μg/L] and percentage of cTnI>0.10μg/L (94.5% vs.54.9%) in combined treatment group, P=0.001 both.Compared with SNP group after 12 months, there was significant rise in left ventricular ejection fraction [(62.29±3.06)% vs.(65.65±3.94)%], and significant reductions in left ventricular end-diastolic dimension[(50.24±3.73)mm vs.(47.60±4.72)mm] and left ventricular end-systolic dimension [(33.29±2.11)mm vs.(31.00±4.33)mm] in combined treatment group, P<0.05 all.There were no significant adverse reactions during hospitalization and follow-up in both groups.Conclusion: When no-reflow occurs during PCI, intracoronary injection of SNP combined verapamil can improve cardiac function, and its safety is good, which is worth extending.
2.Effect of Probucol on Enzyme and Receptors of High Density Lipoprotein During Reverse Cholesterol Transportation in Experimental Rabbits With Atherosclerosis
Jiankai ZHONG ; Yanxian WU ; Yingwen CHEN ; Chen LI ; Wensheng LI ; Zhigang GUO
Chinese Circulation Journal 2016;31(4):393-397
Objective: To explore the effect of probucol on enzyme and receptors of high density lipoprotein (HDL) during reverse cholesterol transportation in experimental rabbits with atherosclerosis. Methods: A total of 24 New Zealand rabbits were randomly divided into 3 groups: Control group, the rabbits were fed by normal diet, High cholesterol group, the rabbits were fed by high cholesterol diet and Probucol group, the rabbits were fed by high cholesterol diet with probucol.n=8 in each group, all animals were treated for 12 weeks. Blood levels of lipids were examined by colorimetric method, serum lecithin cholesterol acyltransferase (LCAT) and cholesterol ester transfer protein (CETP) were detected by ELISA, expressions of ATP binding cassette transporter A1 (ABCA1) and scavenger receptor class B type I (SR-BI) in aortic plaque were measured by immunohistochemistry; the above indexes were compared among different groups.
Results: ① for blood lipids by mmol/L, the following indexes in Probucol group were lower than High cholesterol group: TC (15.95±1.51 vs 21.95±3.71), LDL-C (13.01±2.28 vs 17.90±3.51), HDL-C (0.56±0.10 vs 1.13±0.12), all P<0.01.② the following perimeters in High cholesterol group were lower than Control group: for CETP by μg/ml (1.24±0.54 vs 2.07±0.64), for LCAT by μg/ml (15.02±3.81 vs 27.01±8.26), all P<0.05; compared with High cholesterol group, Probucol group had increased CETP (3.43±1.01) and LCAT (38.10±7.96), all P<0.05. ③ positive expressions of ABCA1 and SR-BI in aortic plaque in Probucol group were higher than High cholesterol group: for ABCA1 by % (46.81±10.01 vs 24.10±8.48), for SR-BI by % (48.04±10.90 vs 18.61±6.77), all P<0.01.
Conclusion: Probucol may increase blood levels of LCAT, CETP via up-regulating the expressions of ABCA1, SR-B1 and elevating the reverse cholesterol transportation of HDL, therefore improve HDL function in experimental rabbits with atherosclerosis.
3.Occurrence and prognosis of coronary slow flow in emergency percutaneous coronary intervention: correlations with homocysteine.
Yanxian WU ; Jiankai ZHONG ; Yuying CHEN ; Yingwen CHEN ; Wensheng LI ; Saizhu WU
Journal of Southern Medical University 2013;33(3):416-419
OBJECTIVETo investigate the correlation of the occurrence and prognosis of coronary slow flow phenomenon (CSF) with blood homocysteine (Hcy) levels in patients receiving emergency percutaneous coronary intervention therapy (PCI).
METHODSFrom January, 2010 to December, 2011, 138 patients with ST-elevation myocardial infarction received emergency angioplasty, among whom 46 patients developed CSF and 92 did not (control group). Blood Hcy levels were determined in these patients. The patients with CSF were classified into two groups with mild and moderate Hcy elevations (32 and 14 cases, respectively), and the left ventricular ejection fraction (LVEF) during hospitalization and at 3 months of follow-up as well as major adverse cardiac events (MACE) were compared between the two groups and analyzed for their association with Hcy level.
RESULTSThe patients with CSF showed significantly higher blood Hcy levels than the control patients (P=0.001). At 3 months of follow-up, the patients with CSF and moderate Hcy elevation had significantly lower LVEF (P=0.031) and higher incidence of MACE (P=0.019) than those with mild Hcy elevation. Hcy levels were negatively correlated with LVEF (r=-0.310, P=0.036) and positively with MACE (r=0.342, P=0.02).
CONCLUSIONA high blood Hcy level is closely correlated with the occurrence of CSF in emergency PCI, affects the recovery of LVEF and increases the incidence of MACE.
Adult ; Aged ; Coronary Artery Disease ; blood ; diagnosis ; therapy ; Emergency Treatment ; Female ; Homocysteine ; blood ; Humans ; Male ; Middle Aged ; Percutaneous Coronary Intervention ; Prognosis ; Stroke Volume ; Treatment Outcome ; Ventricular Function, Left